Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
PHASE3
The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 m...
Status
Completed
Location
205.419.01058 Boehringer Ingelheim Investigational Site
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
PHASE3
The trial is a randomised, double-blind, placebo-controlled, parallel-group...
Status
Completed
Location
205.417.01061 Boehringer Ingelheim Investigational Site
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
PHASE3
The trial is a randomised, double-blind, placebo-controlled, parallel-group...
Status
Completed
Location
205.416.01007 Boehringer Ingelheim Investigational Site
Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)
PHASE2
The primary objective of this study is to determine the optimum dose(s) of ...
Status
Completed
Location
1237.9.00152 Boehringer Ingelheim Investigational Site
A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale
PHASE4
To demonstrate the efficacy of inhaled tiotropium + olodaterol via Respimat...